You are viewing: Europe Multiomics Market analysis
Part of: Multiomics Market (Global)

The Europe Multiomics Market was valued at $886.7 Million in 2026 and projected to reach to $1534.8 Million by 2031, representing a compound annual growth rate of 11.6%. Europe's multiomics market is poised for sustained growth through 2031, driven by increasing healthcare expenditure, regulatory support for precision medicine, and growing clinical adoption across major economies.

Europe Multiomics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Multiomics Market Trends and Insights

  • This growth trajectory reflects Europe's strong investment in precision medicine infrastructure and advanced genomic research capabilities.
  • Europe is leveraging its established healthcare systems and regulatory frameworks to accelerate multiomics adoption across clinical diagnostics, drug development, and personalized medicine applications. The European multiomics sector benefits from substantial government funding, collaborative research initiatives, and a growing number of biotech companies integrating multi-layered omics data.
  • Europe's commitment to data standardization and interoperability standards positions the region as a leader in translating multiomics insights into clinical practice.
  • Between 2026 and 2031, Europe is expected to see increased adoption across pharmaceutical companies, academic medical centers, and specialized diagnostic laboratories. Key drivers propelling Europe's market include rising prevalence of chronic diseases, regulatory support for precision diagnostics, and expanding partnerships between European research institutions and industry players.
  • Europe's multiomics market growth at 11.6% CAGR underscores the region's pivotal role in advancing integrated omics-based healthcare solutions..

Key Market Statistics

  • CAGR (2026-2031) 11.6% CAGR
  • Market Size, 2026 ~USD 886.7 Million
  • Forecast, 2031 ~USD 1534.8 Million
  • Geography Europe

Europe Multiomics Market Overview

Market Valuation & Growth :

Europe's multiomics market is valued at $886.7 million in 2026, expanding at a CAGR of 11.6% to reach $1,534.8 million by 2031, demonstrating strong regional momentum in precision medicine adoption.

Healthcare Infrastructure Leadership :

Europe's established healthcare systems and robust regulatory frameworks position the region as a leader in multiomics integration, with Germany, UK, and France driving innovation and clinical implementation.

Precision Medicine Investment :

Significant European investment in genomic research capabilities and precision medicine infrastructure is accelerating multiomics adoption across clinical diagnostics, drug development, and personalized treatment pathways.

Regional Market Concentration :

Germany leads European adoption with $353.7 million in market size, followed by the UK ($296.9 million) and France ($172.3 million), reflecting concentrated innovation hubs in Western Europe.

Europe Multiomics Market Dynamics

  • The region's advanced research infrastructure and collaborative healthcare ecosystems are facilitating rapid integration of multiomics technologies into diagnostic and therapeutic workflows.
  • Germany, UK, and France are establishing themselves as innovation centers, with expanding partnerships between academic institutions, pharmaceutical companies, and healthcare providers accelerating market penetration and clinical validation of multiomics applications..

Market Ecosystem

logo-mobile

MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina)
company logo
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Europe's multiomics market is valued at $886.7 million in 2026 and is projected to grow to $1,534.8 million by 2031, representing an 11.6% CAGR.
    • Europe leads in precision medicine adoption, supported by robust regulatory frameworks and substantial government funding for genomic research initiatives.
    • European pharmaceutical and diagnostic companies are increasingly integrating multiomics data to enhance drug development and clinical decision-making.
    • Europe's focus on data standardization and interoperability is establishing the region as a global benchmark for translating multiomics insights into clinical applications.

    Multiomics Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SERVICES (Offering)
    Forecast Period 2026-2031
    Growth Rate CAGR of 12.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 3.19 (2026)
    Revenue Forecast (Billions) ~USD 5.7 (2031)
    Segments Covered Offering, Type, Technology, Method, Workflow, Application, End User

    Europe Multiomics Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Assay Kits & Reagents
    • Consumables
    • Instruments & Software
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Nanopore Sequencing
    • Ngs-Based Proteomics
    • Other Consumables
    • Other Proteomics Methods
    • Other Sequencing Technologies
    • Pcr-Based Proteomics
    • Smrt Sequencing

    By Technology

    • Long-Read Sequencing
    • Nanopore Sequencing
    • Other Sequencing Technologies
    • Other Technologies
    • Proteomics
    • Sequencing
    • Smrt Sequencing

    By Method

    • Chromatin Accessibility Sequencing
    • Chromatin Interaction Analysis
    • Dna Methylation Sequencing
    • Epigenomics
    • Histone Modification Profiling
    • Long-Range Sequencing
    • Long-Read & Long-Range Sequencing
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Ngs-Based Proteomics
    • Other Epigenomics Methods
    • Other Long-Read & Long-Range Sequencing Methods
    • Other Methods
    • Other Proteomics Methods
    • Other Single-Cell Omics
    • Other Spatial Omics
    • Pcr-Based Proteomics
    • Proteomics
    • Sequencing-Based Epigenomics
    • Single-Cell Epigenomics
    • Single-Cell Genomics
    • Single-Cell Omics
    • Single-Cell Proteomics
    • Single-Cell Transcriptomics
    • Spatial Epigenomics
    • Spatial Genomics
    • Spatial Omics
    • Spatial Proteomics
    • Spatial Transcriptomics

    By Workflow

    • Data Visualization & Analysis
    • Sample Preparation
    • Sequencing & Analysis/ Sample Characterization
    • Sequencing & Analysis/Sample Characterization

    By Application

    • Biomarker Discovery
    • Cell Biology
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Immunology
    • Neurology
    • Oncology
    • Other Applications
    • Precision Medicine
    • Translational Research

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Hospitals & Diagnostic/Clinical Laboratories
    • Pharmaceutical & Biotechnology Companies

    Target Audience

    • Pharmaceutical & Biotech Companies : Require detailed European market intelligence to guide drug development strategies, precision medicine partnerships, and multiomics-enabled clinical trial designs across regulated markets.
    • Diagnostic & Laboratory Service Providers : Need market sizing and growth forecasts to plan service expansion, technology investments, and competitive positioning in Europe's rapidly evolving multiomics diagnostics landscape.
    • Healthcare System Administrators : Seek evidence-based market data to inform precision medicine infrastructure investments, multiomics integration roadmaps, and budget allocation decisions across European healthcare networks.
    • Medical Device & Software Developers : Require regional market analysis to identify growth opportunities, regulatory pathways, and customer segments for multiomics platforms and analytical tools in European healthcare.
    • Investment & Strategy Consultants : Need comprehensive European market data to support M&A due diligence, portfolio strategy development, and investment thesis validation in the multiomics healthcare sector.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 2546.4 Million · 12.6% wtd CAGR ·
    Asia Pacific
    ~USD 1341.2 Million · 13.4% wtd CAGR ·
    Latin America
    ~USD 142.8 Million · 10.7% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 353.7 Million
    UKUSD 296.9 Million
    FranceUSD 172.3 Million
    ItalyUSD 112 Million
    SpainUSD 98.5 Million
    Rest Of EuropeUSD 356.9 Million

    Country market size visualization

    Germany
    USD 353.7 Million
    UK
    USD 296.9 Million
    France
    USD 172.3 Million
    Italy
    USD 112 Million
    Spain
    USD 98.5 Million
    Rest Of Europe
    USD 356.9 Million

    Reasons to Buy this Report

    • Regional Market Segmentation : Detailed breakdown of Europe's multiomics market by country, including Germany, UK, France, Italy, and Spain, enabling targeted market entry and competitive positioning strategies.
    • Growth Trajectory Insights : Comprehensive analysis of the 11.6% CAGR growth from 2026-2031, identifying key drivers, market dynamics, and expansion opportunities specific to European healthcare systems.
    • Regulatory & Infrastructure Analysis : In-depth examination of Europe's healthcare regulatory frameworks, precision medicine policies, and research infrastructure supporting multiomics adoption and clinical implementation.
    • Competitive Landscape Mapping : Strategic insights into leading European multiomics providers, innovation hubs, and partnership ecosystems across Germany, UK, and France to inform competitive strategies.
    • Investment & Expansion Planning : Data-driven guidance for pharmaceutical, diagnostic, and healthcare technology companies planning European market entry, expansion, or partnership development in the multiomics sector.

    Frequently asked questions

    What is the current size of Europe's multiomics market in 2026?

    Europe's multiomics market is valued at $886.7 million in 2026, reflecting strong adoption of integrated omics technologies across the region's healthcare and research sectors.

    What is the projected market size for Europe's multiomics sector by 2031?

    Europe's multiomics market is forecast to reach $1,534.8 million by 2031, driven by increased precision medicine adoption and regulatory support for advanced diagnostics.

    What is the CAGR for Europe's multiomics market between 2026 and 2031?

    Europe's multiomics market is expected to grow at an 11.6% compound annual growth rate (CAGR) from 2026 to 2031, outpacing many other healthcare technology segments.

    Which sectors are driving growth in Europe's multiomics market?

    Europe's multiomics growth is driven by pharmaceutical R&D, clinical diagnostics, personalized medicine initiatives, and academic research institutions leveraging integrated omics data.

    How does Europe's multiomics market compare to global trends?

    Europe's 11.6% CAGR is slightly below the global 12.3% CAGR, but Europe maintains leadership in precision medicine infrastructure, regulatory standards, and data interoperability frameworks.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Multiomics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Multiomics Market : Top-Down and Bottom-Up Approach

    Multiomics Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.

    Key Stakeholders

    • Multiomics product & service providers
    • Multiomics bioinformatics/data analysis companies
    • Venture capitalists and other government funding organizations
    • Research and consulting firms
    • Hospitals and diagnostic clinics
    • Pharmaceutical and biotechnology companies
    • Academic and government research institutes
    • Life science companies

    Report Objectives

    • To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe multiomics market, by country
    • Further breakdown of the Rest of Asia Pacific multiomics market, by country

    Company Analysis

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Multiomics Market Report

    Full forecast, segment splits, and company analysis for all Multiomics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status